List of ongoing clinical trial - Shuang Ho Hospital
|
Symptom
|
IRB NO.
|
Clinical trial title
|
Principal Investigator
|
Department
|
Assistant Phone
|
|
Focal Segmental Glomerulosclerosis
|
N202203001
|
A pivotal phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of dmx-200 in patients with focal segmental glomerulosclerosis (fsgs) who are receiving an angiotensin ii receptor blocker (arb)
|
Mai-Szu
Wu
|
Nephrology
|
Ya-Chun
Chang
0976909019
|
|
Nephropathy
|
N202402003
|
A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy (igan)
|
Mai-Szu
Wu
|
Nephrology
|
Yun-Hui
Wang
0972223815
|
|
Chronic Kidney Disease
|
N202206023
|
A phase 3 randomized controlled study of renal autologous cell therapy (react) in subjects with type 2 diabetes and chronic kidney disease (regen-006)
|
Mai-Szu
Wu
|
Nephrology
|
Yun-Hui
Wang
0972223815
|
|
Lung Cancer
|
N201810016
|
A phase iii, double-blind, placebo controlled, multi-center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages ii and iii non-small cell lung cancer (aegean)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N201903127
|
A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N201912030
|
A phase 3, randomized, doubleblind study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemothera py plus placebo, followed by surgical resection and adjuvant treatment with nivolumab o r placebo for participants with resectable stage ii-iiib non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Lung Cancer
|
N202004125
|
A phase iii, randomised, controlled, multi-centre, 3-arm study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy versus standard of care chemotherapy alone for the treatment of patients with epidermal growth factor receptor mutation positive, resectable non-small cell lung cancer (neoadaura)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Lung Cancer
|
N202005083
|
A phase 2 study to evaluate the safety and efficacy of ab122 monotherapy, ab154 in combination with ab122, and ab154 in combination with ab122 and ab928 in front-line, non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202005083
|
A phase 2 study to evaluate the safety and efficacy of ab122 monotherapy, ab154 in combination with ab122, and ab154 in combination with ab122 and ab928 in front-line, non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202005126
|
A phase 3, randomized, open label study to compare nivolumab plus concurrent chemoradiotherapy (ccrt) followed by nivolumab plus ipilimumab or nivolumab plus ccrt followed by nivolumab vs ccrt followed by durvalumab in previously untreated, locally advanced non-small cell lung cancer (la nsclc)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202009060
|
A phase ii, single arm study assessing the efficacy of osimertinib in combination with savolitinib in patients with egfrm+ and met+, locally advanced or metastatic non small cell lung cancer who have progressed following treatment with osimertinib (the savannah study)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202010052
|
A phase ii, single arm study assessing the efficacy of osimertinib in combination with savolitinib in patients with egfrm+ and met+, locally advanced or metastatic non small cell lung cancer who have progressed following treatment with osimertinib (the savannah study)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202011026
|
A phase 3, randomized study of amivantamab and lazertinib combination therapy versus osimertinib versus lazertinib as first-line treatment in patients with egfr-mutated locally advanced or metastatic non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202012007
|
A randomized, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with egfr exon 20ins mutated locally advanced or metastatic non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202108070
|
A phase ib multicenter, open-label dose-escalation study to evaluate the safety and tolerability of trastuzumab deruxtecan (t-dxd) and durvalumab in combination with cisplatin, carboplatin or pemetrexed in first-line treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (nsclc) and human epidermal growth factor receptor 2 overexpression (her2+) (destiny-lung03)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Lung Cancer
|
N202110055
|
An open-label, randomized, multicenter, phase 3 study to assess the efficacy and safety of trastuzumab deruxtecan as first-line treatment of unresectable, locally advanced, or metastatic nsclc harboring her2 exon 19 or 20 mutations (destiny-lung04)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202201004
|
A phase iii, double-blind, randomised, placebo-controlled, international study to assess the efficacy and safety of adjuvant osimertinib versus placebo in participants with egfr mutation-positive stage ia2-ia3 non-small cell lung cancer, following complete tumour resection (adaura2)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Lung Cancer
|
N202202008
|
A phase 3, open-label, randomized study of amivantamab and lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with egfr-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure.
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Lung Cancer
|
N202204040
|
A phase iii, double-blind, placebo-controlled, randomised, multicentre, international study of durvalumab plus oleclumab and durvalumab plus monalizumab in patients with locally advanced (stage iii), unresectable non-small cell lung cancer (nsclc) who have not progressed following definitive, platinum-based concurrent chemoradiation therapy (pacific 9)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202208028
|
A randomized, open-label, phase 2 study to evaluate obi-833/obi-821 in combination with first-line erlotinib in patients with egfr-mutated, globo h-positive, locally advanced or metastatic non-small cell lung cancer
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202303061
|
A phase iii, randomised, open- label, multicentre, global study of datopotamab deruxtecan (dato- dxd) in combination with durvalumab and carboplatin versus pembrolizumab in combin ation with platinum-based chemotherapy for the first- line treatment of patients with locally advanced or metastatic nsclc without actionabl e genomic alterations (d926nc00001; avanzar)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Cancer
|
N202312002
|
A phase ii, open-label, multicentre, randomised study of neoadjuvant and adjuvant treatment in patients with resectable, early-stage (ii to iiib) non-small cell lung cancer (neocoast-2)
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Chronic Obstructive Pulmonary Disease
|
N201910049
|
A randomized, double-blind, placebo-controlled, multi-regional phase iii clinical study of toripalimab alone or in combination with tifcemalimab (js004/tab004) as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy
|
Kang-Yun Lee
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Skin Disease
|
N202012035
|
A phase i, open label, dose escalation study to evaluate the safety and tolerability after intravenous infusion of umc119-06 in subjects with moderate chronic obstructive pulmonary disease (copd)
|
Woan-Ruoh Lee
|
Dermatology
|
Lu-Fan
Lai
0970747584#2388
|
|
Chronic Plaque Psoriasis
|
N202102073
|
Development of stem cell culture technology in vitro - hair follicle and skin sample collection
|
Woan-Ruoh Lee
|
Dermatology
|
Lu-Fan
Lai
0970747584#2388
|
|
Atopic Dermatitis
|
N202307012
|
Prospective observational cohort study of patients with moderate to severe chronic plaque psoriasis in taiwan
|
Woan-Ruoh Lee
|
Dermatology
|
Ya-Chun
Chang
0976909019
|
|
Myasthenia Gravis
|
N202212018
|
An open-label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis
|
Hou-Chang Chiu
|
Neurology
|
Yi-Ping
Ji
0958790027
|
|
Systemic Lupus Erythematosus
|
N202212013
|
A phase 3, randomized, double-blind, placebo-controlled, parallel, multicenter study to evaluate the safety and efficacy of alxn1720 in adults with generalized myasthenia gravis
|
Yu-Sheng Chang
|
Allergy, Immunology and Rheumatology
|
Ci-Han
Chen
0911913137
|
|
Proliferative Lupus Nephritis
|
N202110016
|
A multicentre, randomised, double-blind, placebo-controlled, phase iii study evaluating the efficacy and safety of anifrolumab in asian participants with active systemic lupus erythematosus
|
Yu-Sheng Chang
|
Allergy, Immunology and Rheumatology
|
Ci-Han
Chen
0911913137
|
|
Nephropathy
|
N202203156
|
A multicenter randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of anifrolumab in adult patients with active proliferative lupus nephritis
|
Yung-Ho Hsu
|
Nephrology
|
Yun-Hui
Wang
0972223815
|
|
Tibial Fracture
|
N202201030
|
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in subjects with immunoglobulin a nephropathy
|
Chih-Hwa Chen
|
Orthopedics
|
Shin-Jiun
Tsai
02-2490088#8878
|
|
Knee Osteoarthritis
|
N202210066
|
A randomized, evaluator-blinded, controlled study to evaluate the safety and clinical performance of oif/β-tcp in patients with open tibial fractures in need of bone grafting.
|
Chih-Hwa Chen
|
Orthopedics
|
Shin-Jiun
Tsai
02-2490088#8878
|
|
Ulcerative Colitis
|
N202210056
|
A phase i-ii, dose-escalation, double-blinded, placebo-controlled, and dose-finding study to evaluate the safety and efficacy of 2ccpa in patients with osteoarthritis of the knee
|
Ming-Yao Chen
|
Gastroenterology
|
Jheng-Yi
Liou
0979448117
|
|
Asthma
|
N202208003
|
A phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral ozanimod to evaluate efficacy and long-term safety in chinese participants with moderately to severely active ulcerative colitis (uc)
|
Chen Kuan-Yuan
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Lung Disease
|
N202101017
|
Patient-reported outcomes of benralizumab in real-world use in severe eosinophilic asthma patients in taiwan (beat)
|
Tzu-Tao Chen
|
Pulmonary Medicine
|
Cing-Mei
Chen
0970746955
|
|
Atrial Fibrillation
|
N202201024
|
Non-interventional collecting evidences for ild in taiwan: optimized novel therapy
|
Lung Chan
|
Neurology
|
Shin-Jiun
Tsai
02-2490088#8878
|
|
Ischemic Stroke
|
N202205015
|
An open-label study to evaluate the effectiveness and safety of ezypro® in atrial fibrillation detection in nearly embolic stroke of undetermined source (esus) patient
|
Lung Chan
|
Neurology
|
Shin-Jiun
Tsai
02-2490088#8878
|
|
Ischemic Stroke
|
N202305029
|
A phase ii, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of lt3001 drug product in subjects with acute ischemic stroke (ais)
|
Lung Chan
|
Neurology
|
Shin-Jiun
Tsai
02-2490088#8878
|
|
Lung Cancer
|
N201905120
|
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven phase 3 study of the oral fxia inhibitor asundexian (bay 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk tia
|
Po-Hao Feng
|
Pulmonary Medicine
|
Rong-Wei
Jhou
0963969166
|
|
Atopic Dermatitis
|
N202303137
|
A phase iii, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (egfr) mutation-positive, locally advanced or metastatic non-small cell lung cancer (flaura2)
|
Chia-Lun Chou
|
Dermatology
|
Ya-Chun
Chang
0976909019
|
|
Breast Cancer
|
N202102065
|
A phase i/iia study to evaluate the safety, tolerability and pharmacokinetics of gmxantho in healthy volunteers and to investigate its efficacy and safety profile in atopic dermatitis patients.
|
Tsu-Yi
Chao
|
Hematology and Oncology
|
Jheng-Yi
Liou
0979448117
|
|
Breast Cancer
|
N202307004
|
Phase iii study of trastuzumab deruxtecan (t-dxd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in her2-positive, first-line metastatic breast cancer (destiny-breast09)
|
Tsu-Yi
Chao
|
Hematology and Oncology
|
Jheng-Yi
Liou
0979448117
|
|
Cancer Pain
|
N202012049
|
A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with hormone receptor-positive (hr+)/human epidermal growth factor receptor 2 negative (her2−) (her2 ihc0 or her2-low [ihc 1+, ihc 2+/ish−]) inoperable, locally advanced, or metastatic breast cancer and have received endocrine therapy
|
Tsu-Yi
Chao
|
Hematology and Oncology
|
Jheng-Yi
Liou
0979448117
|
|
Breast Cancer
|
N202012037
|
An exploratory, randomised, double-blind, parallel-group, placebo-controlled phase iia study to assess the analgesic activity of pax-1 in patients with persistent cancer pain.
|
Wei-Hong Cheng
|
Hematology and Oncology
|
Jheng-Yi
Liou
0979448117
|
|
Solid Tumors
|
N202104068
|
Serena-4: a randomised, multicentre, double-blind, phase iii study of azd9833 (an oral serd) plus palbociclib versus anastrozole plus palbociclib for the treatment of patients with estrogen receptor-positive, her2-negative advanced breast cancer who have not received any systemic treatment for advanced disease
|
Wei-Hong Cheng
|
Hematology and Oncology
|
Cih Cuei
0915521015
|
|
Solid Tumors
|
N202210086
|
A phase i, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of ob318 in patients with advanced solid malignancies
|
Wei-Hong Cheng
|
Hematology and Oncology
|
Yi-Ping
Ji
0958790027
|
|
Solid Tumors
|
N202404021
|
A phase i, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability of modified salmonella typhimurium sgn1 administered via intratumoral injection in patients with advanced solid tumors
|
Wei-Hong Cheng
|
Hematology and Oncology
|
Siao-Yu
Liou
0937518688
|
|
Melanoma
|
N202401013
|
A phase 1/2a, multicenter, open-label, first in human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of db-1311 in subjects with advanced/metastatic solid tumors
|
Yao-Yu Hsieh
|
Hematology and Oncology
|
Jheng-Yi
Liou
0979448117
|